Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Post by Raypandaon Jan 27, 2020 7:44pm
124 Views
Post# 30605956

Linneo Health Receives EU-GMP Certification

Linneo Health Receives EU-GMP Certification

"Our partnership with Linneo Health is part of our strategic priority to accelerate international market growth," said Barry Fishman, Chief Executive Officer of VIVO. "We are excited to have an EU-GMP certified source of medical cannabis located within Europe. Through this partnership, we expect to be able to supply the European high-growth market with premium medical cannabis products and services. Our European based supply will allow VIVO to contribute to addressing the unmet medical needs of patients in Germany, which is one of our key target markets for international expansion."

In late March 2019, VIVO’s German subsidiary, ABcann Germany GmbH ("ABcann Germany"), was granted its pharmaceutical wholesale license and GDP-certificate by the responsible authorities of the state of Brandenburg. VIVO is now pursuing narcotic and import license applications in Germany to facilitate imports from other non-EU countries, including Canada, and expects to have its first products sold in the German market in early 2020.

In early February 2019, VIVO exported three of its proprietary cultivars, covering a broad range of cannabinoid profiles, to Linneo Health in Spain. These cultivars were propagated to form VIVO’s genetic basis for commercial cultivation in Europe. The agreement between ABcann Germany and Linneo Health is part of a long-term growth strategy of cooperation, the first step of which is the cultivation of EU-GMP certified cannabis, and represents the foundation on which VIVO and Linneo Health intend to complete the regulatory work required for the launch of medical cannabis in Europe, using a focused and phased approach.

"This agreement with VIVO Cannabis is a significant milestone for Linneo Health, as it strengthens our presence in international markets, consolidates our position as the partner of choice for the pharmaceutical industry, and will help us bring top quality cannabis products to patients in need," said Jos Antonio de la Puente, Chief Executive Officer of Linneo Health.

 
<< Previous
Bullboard Posts
Next >>